H.Res. 1179: Expressing the sense of the House of Representatives that biotechnology firms meeting small business standards are critical to the United States, its people and its economy because they create new medicines, services, and jobs and meet unmet needs related to populations and patients with infectious and chronic diseases, including those of medically underserved populations.
Before you vote › Federal bills
H.Res. 1179: Expressing the sense of the House of Representatives that biotechnology firms meeting small business standards are critical to the United States, its people and its economy because they create new medicines, services, and jobs and meet unmet needs related to populations and patients with infectious and chronic diseases, including those of medically underserved populations.
111th Congress · introduced 2010-03-12 · Health · Latest: Referred to the House Committee on Energy and Commerce.
federal
Follow this bill, step by step
- Where it came from: introduced 2010-03-12 · official record
- Who proposed it: Rep. Davis, Danny K. [D-IL-7] · what a sponsor is
- What happened next: no floor votes in our records yet. Why?
- Where it stands now: Referred to the House Committee on Energy and Commerce. Not final yet: this can still change. We check for updates every day.
- If it becomes law and spends money: follow the money to money laws, then agencies and contracts and grants.
Official title
Expressing the sense of the House of Representatives that biotechnology firms meeting small business standards are critical to the United States, its people and its economy because they create new medicines, services, and jobs and meet unmet needs related to populations and patients with infectious and chronic diseases, including those of medically underserved populations.
Plain summary
Recognizes: (1) that the public deserves the safest, most effective, and efficient processes to save the lives of people living in the United States with infectious and chronic diseases; and (2) the need to coordinate existing public funding to help small business biotechnology firms whose products may be lost due to domestic economic conditions, and to fund critical paths for small biotechnology drug development and for regulatory review and commercial approval. Expresses support for: (1) the domestic development and commercialization of biotechnology research by firms meeting small business size standards and collaborations with university-based biotechnology research facilities; and (2) the advancement of U.S.-based commercialization of point of care therapeutics and diagnostics by emerging and small business biotechnology firms for domestic and global use. Encourages: (1) the development of a national strategic framework to facilitate technological advancements in improving the commercialization processes for small business biotechnology firms; (2) the creation of incentives for small business biotechnology companies that perform basic and applied research through the development and commercialization of biotechnology products and processes and their diffusion into national and local economies; (3) the development of a comprehensive approach to describing disease populations and the production of comprehensive research programs that are current with evolving biotechnology and the unmet needs of diverse patient populations; and (4) the Office of the Secretary of Health and Human Services (HHS) to develop a Federal Biotechnology Coordinating Council representative of small business biotechnology companies, research facilities, and federal agencies with a strategic initiative to facilitate development and preserve these small business biotechnology firms and coordinate resources and funding mechanisms.
Congressional Research Service summary (Introduced in House), quoted unchanged (nonpartisan). Read the source.
What a vote does
A “Yea” vote
A Yea supports adopting this resolution.
A “Nay” vote
If it is not passed, current law stays as it is.
PSI Sci description of the legislative step (not an opinion).
What does this mean? (plain words)
Official text
Expressing the sense of the House of Representatives that biotechnology firms meeting small business standards are critical to the United States, its people and its economy because they create new medicines, services, and jobs and meet unmet needs related to populations and patients with infectious and chronic diseases, including those of medically underserved populations.
Source: Congressional Research Service summary (Introduced in House)
AI explanation – may be wrong, check the official text
No AI explanation yet. It takes up to a minute to write and is then saved for everyone.
Limited to a few requests an hour per person.
The strongest published arguments
Arguments for (supporters)
Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.
Arguments against (opponents)
Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.
Alternatives
Needs sources: no published alternatives yet (for example a different bill, a law instead of an amendment, or keeping current law). We only show items backed by a published source. Suggest one.
How did my representative vote? · This bill's floor votes
Officials and money
Sponsor: Rep. Davis, Danny K. [D-IL-7] · 1 cosponsors
Cost estimate: No cost estimate published yet.
Cosponsors on this site
Sponsor's campaign money: Rep. Davis, Danny K. [D-IL-7] reported raising $100,598 (2025–2026). Details. Shown for context only; it does not mean any donor supported this bill.
No linked floor roll calls in our collected records yet. This does not mean the bill has never had a vote. Check the official bill history.
Words on this page, explained (3)
- Ballot initiative
- A proposed law or constitutional amendment that citizens place on the ballot by gathering enough voter signatures, so voters decide it directly. About half the states allow some form of it.
- Resolution
- A formal statement or decision by a legislative body. Simple resolutions often only express an opinion or set rules for one chamber; they do not become law.
- Roll-call vote
- A vote where each member's position is recorded by name, so the public can see how every member voted. "Yea" means yes, "Nay" means no, "Present" means the member was there but did not take a side.
Plain meanings written from linked sources. All words.
Sources
- Congressional Research Service summary (Introduced in House)
- Congress.gov
- Data: GovInfo BILLSTATUS bulk data (Library of Congress), BILLSTATUS-111hres1179.xml <https://www.govinfo.gov/bulkdata/BILLSTATUS/111/hres>
Record fed-us-cong111-hres1179 · catalog fed-us-congress-bills-cong111 · updated 2026-11-15 by psicol fed-bills-cong111